NCT06171139Recruiting
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
Developing and Testing a Patient-centered Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Metastatic Prostate Cancer
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 6 Dec 2023
- Start date
- 1 Dec 2023
- Primary completion date
- 31 May 2027
- Lead sponsor
- University of California, San Francisco
- Diseases
- Prostate cancer
- NCT number
- NCT06171139
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 1 Dec 2023 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindication to any study-related procedure or assessment in either stage.
Who the study is looking for
- Stage 1:
- Age 18-years-old or older
- Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race, including Black or African American, is included.
- Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Able to understand a written information sheet and willing to verbally consent.
- Fluent in English (reading, writing, and speaking)
- Stage 2:
- Age 18-years-old or older
- Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race, including Black or African American, is included.
- Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Fluent in English (reading, writing, and speaking).
- Anticipated discussion of TGT within 0-365 days of enrollment, per treating oncology provider's discretion. TGT involves the use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:
- Somatic DNA testing of already-collected tissue.
- Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
- Blood-based DNA testing to evaluate for circulating tumor DNA.
- Able to understand a written informed consent document and willing to sign it.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.